Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
Roche dumps another partnered asset.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
